Novartis AG vs UnitedHealth Group Inc — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while UnitedHealth Group Inc trades at $404.95 (market cap $361.00B). The key difference: UnitedHealth Group Inc is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | UNH | |
|---|---|---|
Market Cap | $295.37B | $361.00B |
Sector | Health | Health |
52-Week High | $168.62 | $436.35 |
52-Week Low | $119.31 | $259.02 |
Enterprise Value | $336.69B | $402.86B |
Dividend Yield | 3.07% | 2.31% |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.
UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →